United Therapeutics Co. (NASDAQ:UTHR - Get Free Report) CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction dated Friday, April 26th. The stock was sold at an average price of $235.20, for a total value of $846,720.00. Following the completion of the sale, the chief executive officer now directly owns 130 shares in the company, valued at $30,576. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
United Therapeutics Price Performance
United Therapeutics stock opened at $238.26 on Tuesday. United Therapeutics Co. has a 12-month low of $204.44 and a 12-month high of $261.54. The company has a current ratio of 4.41, a quick ratio of 4.28 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $234.21 and a 200-day moving average price of $228.80. The firm has a market capitalization of $11.21 billion, a PE ratio of 12.01 and a beta of 0.52.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, topping analysts' consensus estimates of $4.28 by $0.08. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The company had revenue of $614.70 million for the quarter, compared to analyst estimates of $575.01 million. During the same period in the prior year, the company posted $2.67 EPS. The firm's revenue for the quarter was up 25.1% on a year-over-year basis. As a group, equities research analysts forecast that United Therapeutics Co. will post 23.45 EPS for the current year.
Institutional Investors Weigh In On United Therapeutics
Dems have chosen Biden replacement?
From Paradigm Press | Ad
On November 16, 2023…
Joe Biden accidentally revealed the name of the candidate…
Who will replace him in the 2024 presidential election.
See who it is HERE.
Several hedge funds and other institutional investors have recently modified their holdings of UTHR. Rise Advisors LLC purchased a new position in United Therapeutics during the 1st quarter valued at $32,000. GAMMA Investing LLC purchased a new stake in shares of United Therapeutics during the fourth quarter valued at $43,000. Benjamin F. Edwards & Company Inc. grew its holdings in shares of United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company's stock worth $69,000 after purchasing an additional 117 shares during the last quarter. C M Bidwell & Associates Ltd. purchased a new position in United Therapeutics in the 3rd quarter worth about $91,000. Finally, Janiczek Wealth Management LLC increased its stake in United Therapeutics by 21.1% in the 1st quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company's stock worth $111,000 after buying an additional 84 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
A number of analysts have issued reports on UTHR shares. Leerink Partnrs reaffirmed an "outperform" rating on shares of United Therapeutics in a research note on Monday, February 5th. SVB Leerink assumed coverage on shares of United Therapeutics in a research report on Monday, February 5th. They issued an "outperform" rating and a $330.00 price target on the stock. The Goldman Sachs Group upgraded shares of United Therapeutics from a "sell" rating to a "neutral" rating and increased their price objective for the company from $213.00 to $215.00 in a research report on Monday, February 12th. HC Wainwright restated a "buy" rating and issued a $300.00 target price on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, Wells Fargo & Company increased their price target on shares of United Therapeutics from $309.00 to $325.00 and gave the company an "overweight" rating in a report on Thursday, March 7th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $294.25.
View Our Latest Stock Report on UTHR
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
